Technetium-99m labeling and biodistribution of anti-TAC disulfide- stabilized Fv fragment

Journal of Nuclear Medicine

Volumn 38, Issue 2, 1997, Pages 294-300

  Yoo, Tae M ^a   Chang, Hye K ^a   Choi, Chang W ^a   Webber, Keith O ^a   Le, Nhat ^a   Kim, In S ^a   Eckelman, William C ^a   Pastan, Ira ^a   Carrasquillo, Jorge A ^a   Paik, Chang H ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Bldg 21 ^*  (United States)

Author keywords

athymic mice; Fv fragment; monoclonal antibody; radioimmunodetection; technetium 99m

Indexed keywords

ANTIBODY; BENZOYLMERCAPTOACETYL TRIGLYCINE TC 99M; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

ARTICLE; DRUG DISTRIBUTION; DRUG UPTAKE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCINTIGRAPHY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FEMALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOTECHNETIUM COMPOUNDS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECEPTORS, INTERLEUKIN-2; TUMOR CELLS, CULTURED;

EID: 0031038808     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Webber KO, Reiter Y, Brinkmann U, Kreitman R, Pastan I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol Immunol 1995;32:249-258.
2. + cells. J Immunol 1981;126:1393-1397.
3. Whitlow M, Bell BA, Feng SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Engineering 1993;6: 989-995.
4. Pantoliano MW, Bird RE, Johnson LS, et al. Conformational stability, folding and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry 1991;30:10117-10125.
5. Huston JS, McCartney J, Tai MS, et al. Medical applications of single-chain antibodies. Int Rev Immunol 1993;10(2-3):195-217.
6. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-6371.
7. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-4034.
8. King DJ, Mountain A, Adair JR, et al. Tumor localization of engineered antibody fragments. Antibod Immunoconj Radiopharm 1992;5:159-168.
9. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
10. Yokota T, Milenic DE, Whitlow M, et al. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993;51:3776-3783.
11. Reynolds JC, Del Vecchio S, Sakahara H, et al. Antimurine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol 1989;16:121-125.
12. Sakahara H, Reynolds JC, Carrasquillo JA, et al. In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med 1989;30:1311-1317.
13. 125I-labeled anti-Tac disulfide-stabilized Fv fragment in nude mice with IL-2α-receptor-positive tumor xenografts. Cancer Res 1995;55:5323-5329.
14. 99mTc. Nucl Med Biol 1985;12:3-8.
15. 99mTc-labeling method. Nucl Med Biol 1992;19:669-677.
16. Rhodes BA, Zamora PO, Nowell KD, Valdez EF. Technetium-99m labeling of murine monoclonal antibody fragments. J Nucl Med 1986;27:685-693.
17. 99mTc. Nucl Med Biol 1989;16:171-176.
18. Thakur ML, DeFulvia JD. Technetium-99m-monoclonal antibodies for immunoscintigraphy. Simplified preparation and evaluation. J Immunol Methods 1991;137:217-224.
19. Hnatowich DJ, Mardirossian G, Ruschowski M, et al. Directly and indirectly technetium-99m-labeled antibodies; a comparison of in vitro and animal in vivo properties. J Nucl Med 1993;34:109-119.
20. Eckelman WC. Radiolabeling with Tc-99m to study high-capacity and low-capacity biochemical systems. Eur J Nucl Med 1995;22:249-263.
21. George ATJ, Jamar F, Tai M, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Tc-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci USA 1995;92:8358-8362.
22. Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J Nucl Med 1986;27:111-116.
23. Visser GWM, Gerretsen M, Herscheid JDM, Snow GB, Dongen G. Labeling of monoclonal antibodies with Rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-1963.
24. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a singly soluble chloramine 1,3,4,6-tetrachloro-3α,6α-diphenylglycouracil. Biochem Biophy Res Commun 1978;80:849-857.
25. Lindmo T, Boven E, Cuttitta FJF, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 1984;72:77-89.
26. 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. Cancer Res 1993;53:2834-2839.
27. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I. Recombinant immunotoxins containing anti-tac(Fv) and derivatives of pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 1994;83:426-434.
28. Webber KO, Kreitman R, Pastan I. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by IL-2 receptor-hearing tumors. Cancer Res 1995;55:318-323.
29. 18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot 1994;45:1155-1163.
30. Colcher D, Bird R, Roselli M, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990;82:1191-1197.
31. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exper Med 1967;126:207-221.
32. Arend WP, Silberblatt FJ. Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. Clin Exper Immunol 1975;22:502-513.
33. Schott ME, Milenic DE, Yokota T, et al. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res 1992;52:6413-6417.
34. 2 and F(ab) fragments by imaging tumor xenografts. Eur J Nucl Med 1988;13:598-604.
35. 111In. Cancer Res 1987;47:1149-1154.
36. Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labeled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med 1994;21:663-665.
37. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993;67:1437-1439.
38. Brown-Grant K. Extrathyroidal iodide concentrating mechanisms. Physiol Rev 1961; 41:189-213.
39. Paik CH, Yokohama K, Reynolds JC, et al. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor. J Nucl Med 1989;30:1693-1701.